Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

NCT06577987 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

220

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Solid Tumor
Refractory Solid Tumor
Cancer
Lung Cancer
Triple Negative Breast Cancer
Breast Neoplasms
Neuroendocrine Tumors
Neuroendocrine Carcinoma
RB1 Gene Mutation

Interventions

DRUG: CID-078 Monotherapy

Sponsor

Circle Pharma